Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (NYSE: LLY) has launched a new education campaign aimed at raising awareness of breast cancer recurrence risks. Collaborating with organizations like Breastcancer.org and Living Beyond Breast Cancer, the initiative focuses on individuals diagnosed with hormone receptor-positive, HER2-negative early breast cancer. With over 290,000 expected diagnoses in the U.S. in 2022, the campaign provides resources to help patients understand individual risk factors for recurrence. Educational materials include a digital fact sheet and patient conversation guide.
Eli Lilly (NYSE: LLY) announced that the FDA has granted Emergency Use Authorization (EUA) for its monoclonal antibody, bebtelovimab, to treat mild-to-moderate COVID-19 in high-risk adults and pediatric patients. The treatment is authorized for patients with positive SARS-CoV-2 tests who lack suitable alternatives. The recommended dose is 175 mg via intravenous injection. Eli Lilly has secured a supply agreement with the U.S. government for 600,000 doses, valued at approximately $720 million. Bebtelovimab retains efficacy against Omicron and other variants of concern.
Eli Lilly and Company (NYSE: LLY) announced a contract with the U.S. government to supply up to 600,000 doses of the investigational COVID-19 treatment, bebtelovimab, for at least $720 million. The agreement is contingent on the drug receiving Emergency Use Authorization (EUA) from the FDA, a request that has been submitted. The projected revenue impact for 2022 is at least $720 million, with an estimated $0.20 in earnings per share (EPS). Bebtelovimab demonstrates strong efficacy against COVID-19 variants, maintaining full neutralizing activity against Omicron and other variants of concern.
Eli Lilly and Company (NYSE: LLY) has appointed Cynthia Cardona as president of the Eli Lilly and Company Foundation and senior director of social impact. Cardona will lead initiatives focused on racial justice, education, and global health. With experience dating back to 2001, she has held various leadership roles within the company, including chief marketing officer for Lilly Japan. The Foundation, established in 1968, aims to improve health and educational opportunities while addressing racial inequities. Forward-looking statements in the PR highlight potential risks linked to leadership changes.
Eli Lilly and Company (LLY) reported strong financial results for Q4 and the full year 2021, showcasing an 8% revenue increase in Q4 to $8 billion and a 15% annual growth to $28.3 billion. The company highlighted significant growth in key products, including Trulicity and Taltz. However, net income decreased by 18% in Q4 and 10% for the year, primarily due to reduced other income and increased operating expenses. Lilly continues to pursue an exciting pipeline and expects 2022 EPS in the range of $8.00 to $8.15, affirming confidence in future growth.
Eli Lilly and Company (NYSE: LLY) has partnered with UNICEF to improve health outcomes for 10 million children and adolescents suffering from chronic non-communicable diseases (NCDs) by 2025. Lilly will contribute $14.4 million to enhance healthcare systems and support health workers in Bangladesh, Malawi, Nepal, the Philippines, and Zimbabwe. This collaboration aims to combat diseases like diabetes and cancer, addressing the crisis where nearly one million children under 20 die annually due to often treatable conditions.
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on February 9, 2022. Key figures, including Jake Van Naarden, CEO of Loxo Oncology at Lilly, and David Hyman, M.D., Chief Medical Officer of Lilly Oncology, will engage in a virtual fireside chat at 12 p.m. Eastern time. Investors can access a live audio webcast through Lilly's Investor website, with a replay available for approximately 90 days thereafter. Eli Lilly remains committed to discovering life-changing medicines and giving back to communities.
Eagle Pharmaceuticals has launched PEMFEXY (pemetrexed for injection), a new treatment for nonsquamous non-small cell lung cancer and mesothelioma. Sales started today, following FDA approval and a settlement with Eli Lilly. The U.S. market for ALIMTA, a competitor, reached $1.2 billion in the past year. The company anticipates substantial revenue growth from PEMFEXY in 2022. With a unique J-code, PEMFEXY is positioned to benefit both patients and providers in the oncology market.
Eli Lilly plans to invest over $1 billion in a new manufacturing site in Concord, North Carolina, creating nearly 600 new jobs. This facility aims to enhance manufacturing capacity for injectable products and leverage advanced technology. The decision reflects Lilly's commitment to growth in the pharmaceutical sector and its ongoing investments in North Carolina, totaling over $4 billion in the past five years. The investment is contingent on local government approvals, and an additional $500 million will be spent on a biopharmaceutical facility in Ireland.
Eli Lilly and Incyte provided updates on the Phase 3 development for OLUMIANT (baricitinib) in systemic lupus erythematosus (SLE) and atopic dermatitis. The Phase 3 lupus program has been discontinued after the SLE-BRAVE-I study met its primary endpoint, while SLE-BRAVE-II did not. Ongoing discussions with the FDA may lead to a Complete Response Letter for the atopic dermatitis sNDA due to lack of alignment on the indicated population. Lilly remains committed to other research with OLUMIANT, including potential regulatory approvals for COVID-19 and alopecia areata in 2022.